Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
Check source scope before reading a dose
UCSF posaconazole - oral DR subset
Product / population
Adults receiving fungal prophylaxis with whole oral 100 mg delayed-release posaconazole tablets. The selected generic label is prophylaxis-only; oral suspension, PowderMix and IV formulations are excluded.
Renal method
Qualitative renal/HD guidance; CVVHD assumption from source
Source revision
Revision date not stated on the reviewed page.
Retrieved
2026-09-05
Local review status
Separate professional-source protocol; not automatically equivalent to product labeling.
University of California San Francisco (UCSF) · Adults receiving fungal prophylaxis with whole oral 100 mg delayed-release posaconazole tablets. The selected generic label is prophylaxis-only; oral suspension, PowderMix and IV formulations are excluded.
Renal method: Qualitative renal/HD guidance; CVVHD assumption from source Source date: Revision date not stated on the reviewed page. Retrieved: 2026-09-05
Separate professional-source protocol; not automatically equivalent to product labeling.
Source-specific renal protocol
For the delayed-release oral tablet portion of its protocol, UCSF uses 300 mg every 12 hours for two doses, then 300 mg every 24 hours without renal or HD dose reduction. It refers to therapeutic drug monitoring and warns that oral solution cannot be substituted. Intermittent HD assumes high-flux treatment; continuous guidance assumes CVVHD at 2 L/hour with residual native GFR.
This local extraction excludes the page's IV and crushed-tablet regimens. The institution uses a broader indication scope than the selected generic prophylaxis-only label.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.